Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Mar;25(2):137-40.

[Peripheral blood mutated p53 DNA and its clinical value in human breast cancer]

[Article in Chinese]
Gen-hong Di  1 , Gang Liu, Jiong Wu, Zhen-zhou Shen, Zhi-min Shao
Affiliations
  • PMID: 12795838

[Peripheral blood mutated p53 DNA and its clinical value in human breast cancer]

[Article in Chinese]
Gen-hong Di et al. Zhonghua Zhong Liu Za Zhi. 2003 Mar.

Abstract

Objective: To evaluate the clinical value of mutated p53 in the peripheral blood of breast cancer patients.

Methods: Plasma DNA of 126 breast cancer patients and 92 healthy women was examined. DNA extraction from the tumor and tissue samples was performed by a nonorganic method. Plasma DNA was purified on Qiagen columns. PCR-SSCP analysis was performed to examine the point mutations in the conserved exons 5, 6, 7 and 8 of TP53.

Results: The mean concentration of plasma DNA was 21 ng/ml in healthy women and 211 ng/ml in patients with breast cancer (P < 0.01). p53 mutations in the primary tumor were detected in 46 of 126 (36.5%) breast cancer patients. Of these 46 patients, 30 (65.1%) were also found to have p53 mutations in their plasma DNA. p53 mutation in plasma DNA was closely correlated with clinical stage, tumor size, lymph node (LN) metastasis and estrogen receptor status (P < 0.05). Survival of the patients with both primary tumor and plasma p53 mutations was the worst. Thirteen of the 22 (59.0%) patients with recurrence and/or metastasis had detectable p53 mutations in their plasma DNA.

Conclusion: p53 mutations in plasma DNA may be a useful prognostic factor and an early marker of recurrence or distant metastasis in breast cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Publication types